Scaffold Hopping of α-Rubromycin Enables Direct Access to FDA-Approved Cromoglicic Acid as a SARS-CoV-2 M<sup>Pro</sup> Inhibitor

Scaffold Hopping of α-Rubromycin Enables Direct Access to FDA-Approved Cromoglicic Acid as a SARS-CoV-2 M<sup>Pro</sup> Inhibitor

The COVID-19 pandemic is still active around the globe despite the newly introduced vaccines. Hence, finding effective medications or repurposing available ones could offer great help during this serious situation. During our anti-COVID-19 investigation of microbial natural products (MNPs), we came...

Full description

Bibliographic Details
Main Authors: Hani A. Alhadrami, Ahmed M. Sayed, Heba Al-Khatabi, Nabil A. Alhakamy, Mostafa E. Rateb
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Pharmaceuticals
Subjects:
COVID-19
<i>Streptomyces collinus</i>
α-rubromycin
in silico
M<sup>Pro</sup>
cromolyn
Online Access:https://www.mdpi.com/1424-8247/14/6/541

Similar Items

Similar Items